Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20252024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis Mar 28, 2012 Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay Mar 20, 2012 Nektar Therapeutics Announces Webcast of Presentation at the 32nd Annual Cowen and Company Healthcare Conference in Boston Mar 02, 2012 Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results Feb 29, 2012 Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million Feb 29, 2012 Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting Feb 27, 2012 Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets Feb 24, 2012 Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 04, 2012 Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR-181, a Novel Opioid Analgesic Molecule to Treat Chronic Pain Dec 13, 2011 Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer Dec 12, 2011 Pagination First page « first Previous page ‹ previous … Page 32 Page 33 Page 34 Page 35 Current page 36 Page 37 Page 38 Page 39 Page 40 … Next page next › Last page last »